The Hyderabad-based Aurobindo Pharma Limited on August 29, 2015 announced that the company has received the final approval from the US Food & Drug Administration (US FDA) to manufacture and market raloxifene hydrochloride tablet USP 60 mg, a bioequivalent and therapeutically equivalent to Evista tablet (60mg) of Eli Lilly.
Raloxifene hydrochloride tablet, is indicated for treatment and prevention of osteoporosis in postmenopausal women, has an estimated market size of $ 404 million for the twelve months ending June 2015, according to IMS.
